PCC0208017

• CAT Number: I034286
• CAS Number: 2623158-64-3
• Molecular Formula: C19H20F3N7
• Molecular Weight: 403.4132
• Purity: 98%
• Synonyms: PCC0208017; PCC-0208017; PCC 0208017
• Target: Apoptosis
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: N4-((1H-Pyrazol-3-yl)methyl)-N2-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-5-(trifluoromethyl)pyrimidine-2,4-diamine
• InChI: InChI=1S/C19H20F3N7/c1-29-7-5-12-8-14(3-2-13(12)11-29)26-18-24-10-16(19(20,21)22)17(27-18)23-9-15-4-6-25-28-15/h2-4,6,8,10H,5,7,9,11H2,1H3,(H,25,28)(H2,23,24,26,27)
• InChIKey: PIESSZHWYCPHQD-UHFFFAOYSA-N
• SMILES: FC(C1=CN=C(NC2=CC3=C(CN(C)CC3)C=C2)N=C1NCC4=NNC=C4)(F)F

PCC0208017 (Cat.No:I034286) is a novel Inhibitor of MARK3/MARK4, Suppressing Glioma Progression in vitro and in vivo. In vitro,PCC0208017 strongly inhibited kinase activity against MARK3 and MARK4, and strongly reduced prolifer-ation in three glioma cell lines. PCC0208017 attenuated glioma cell migration, glioma cell invasion, andangiogenesis. PCC0208017 decreased the phosphorylation ofTau, disrupted microtubule dynamics, and induced a G2/M phase cell cycle arrest. In aninvivoglioma model,PCC0208017 showed robust anti-tumor activity, bloodebrain barrier permeability, and a good oral pharma-cokinetic profile.